Immune privilege or inflammation? Insights into the Fas ligand enigma

Joe O'connell; Aileen Houston; Michael W. Bennett; Gerald C. O'sullivan; Fergus Shanahan

doi:10.1038/85395

Immune privilege or inflammation? Insights into the Fas ligand enigma

Joe O'connell
, Aileen Houston
, Michael W. Bennett
, Gerald C. O'sullivan
, Fergus Shanahan

School of Medicine

University College Cork

Research output: Contribution to journal › Review article › peer-review

Abstract

Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.

Original language	English
Pages (from-to)	271-274
Number of pages	4
Journal	Nature Medicine
Volume	7
Issue number	3
DOIs	https://doi.org/10.1038/85395
Publication status	Published - 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/85395

Cite this

@article{04e398e106b94007b0a32f6e60c19396,

title = "Immune privilege or inflammation? Insights into the Fas ligand enigma",

abstract = "Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.",

author = "Joe O'connell and Aileen Houston and Bennett, \{Michael W.\} and O'sullivan, \{Gerald C.\} and Fergus Shanahan",

year = "2001",

doi = "10.1038/85395",

language = "English",

volume = "7",

pages = "271--274",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Immune privilege or inflammation? Insights into the Fas ligand enigma

AU - O'connell, Joe

AU - Houston, Aileen

AU - Bennett, Michael W.

AU - O'sullivan, Gerald C.

AU - Shanahan, Fergus

PY - 2001

Y1 - 2001

N2 - Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.

AB - Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.

UR - https://www.scopus.com/pages/publications/0035102552

U2 - 10.1038/85395

DO - 10.1038/85395

M3 - Review article

C2 - 11231613

AN - SCOPUS:0035102552

SN - 1078-8956

VL - 7

SP - 271

EP - 274

JO - Nature Medicine

JF - Nature Medicine

IS - 3

ER -

Immune privilege or inflammation? Insights into the Fas ligand enigma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this